A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Avelumab (Primary)
- Indications Carcinoma; Malignant thymoma
- Focus Adverse reactions; Therapeutic Use
- 24 Jul 2024 Planned number of patients changed from 55 to 60.
- 23 Jul 2024 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
- 23 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.